Table 3 Demographics and baseline characteristics
From: TOZAL Study: An open case control study of an oral antioxidant and omega-3 supplement for dry AMD
Variable | Parameter | Treatment Group (n = 37) | Placebo Group (n = 15) |
|---|---|---|---|
Gender, n (%) | Female | 20 (54.1) | 10 (67.0) |
Male | 17 (45.9) | 5 (33.0) | |
Age | Mean ± SD | 76.3 ± 7.8 | 74.7 ± 5.9 |
Range | 54 to 90 | 66 to 85 | |
Ethnicity, n (%) | African American | 1 (2.7) | 0 (0) |
Asian | 1 (2.7) | 0 (0) | |
Caucasian | 34 (91.9) | 15 (100) | |
Hispanic | 1 (2.7) | 0 (0) | |
Current smoker, n (%) | No | 37 (100) | - |
Former smoker, n (%) | No | 25 (67.6) | - |
Yes | 11 (29.7) | - | |
Yes, 27 years ago | 1 (2.7) | - | |
Family history of MD, n (%) | Yes | 9 (24.3) | - |
Diabetes | Yes | 4 (10.8) | - |
Hypertension | Yes | 16 (43.2) | - |
Heart Disease | Yes | 13 (35.1) | - |
Other | Yes | 31 (83.8) | - |
Cataract surgery | Yes | 31 (83.8) | - |
Refractive surgery | Yes | 0 (0) | - |
Glaucoma | Yes | 8 (10.8) | - |
Diabetic retinopathy | Yes | 0 (0) | - |
Mean baseline BCVA (logMAR) | Mean ± SD | 0.41 ± 0.17 | 0.39 ± 0.17 |